Ranibizumab 0.5mg + Ranibizumab 0.5 mg + Verteporfin PDT
Phase 3CompletedDevelopment Stage
Visual Impairment Due to Choroidal Neovascularization (CNV) Secondary to Pathologic Myopia (PM)
Visual Impairment Due to Choroidal Neovascularization (CNV) Secondary to Pathologic Myopia (PM)
Sep 11, 2013 → Sep 14, 2016
About Ranibizumab 0.5mg + Ranibizumab 0.5 mg + Verteporfin PDT
Ranibizumab 0.5mg + Ranibizumab 0.5 mg + Verteporfin PDT is a phase 3 stage product being developed by Novartis for Visual Impairment Due to Choroidal Neovascularization (CNV) Secondary to Pathologic Myopia (PM). The current trial status is completed. This product is registered under clinical trial identifier NCT01922102. Target conditions include Visual Impairment Due to Choroidal Neovascularization (CNV) Secondary to Pathologic Myopia (PM).
Hype Score Breakdown
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01922102 | Phase 3 | Completed |
Competing Products
13 competing products in Visual Impairment Due to Choroidal Neovascularization (CNV) Secondary to Pathologic Myopia (PM)
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| pudexacianinium chloride | Astellas Pharma | Phase 3 | 77 |
| pudexacianinium chloride | Astellas Pharma | Phase 3 | 77 |
| Blink® Tears eye drops + Investigational lipid eye drops | Johnson & Johnson | Phase 1 | 33 |
| Blink® Tears eye drops in a multidose bottle + Preservative-free investigational lubricating eye drops in a Novelia® eyedropper | Johnson & Johnson | Phase 2 | 52 |
| Ranibizumab | Novartis | Phase 3 | 77 |
| Ranibizumab + Aflibercept | Novartis | Approved | 85 |
| Ranibizumab | Novartis | Approved | 85 |
| Sham injections + Ranibizumab 0.5 mg | Novartis | Phase 3 | 77 |
| Ranibizumab + Dexamethasone implant and sham injections | Novartis | Phase 3 | 77 |
| Ranibizumab + Aflibercept | Novartis | Approved | 85 |
| Intravitreal Lucentis 0.5mg | Novartis | Pre-clinical | 23 |
| ZK200775 + ZK200775 + Sodium Chloride | Bayer | Phase 1 | 30 |
| Aflibercept 8 mg (VEGF Trap-Eye, BAY86-5321) | Bayer | Pre-clinical | 20 |